



# The Long Island Society of Health-system Pharmacists

## MEETING NOTICE

**DATE:** March 26, 2009

**LOCATION:** DeMatteis Center  
101 Northern Blvd  
Greenvale, NY 11548  
(516) 629-2000

**Please Note – This is NOT St. Francis Hospital**

**TIME:** 6:00 PM – Registration, Dinner and Educational Program

**SPEAKERS:** Pharmacy Residents:

- Tanya Lindsay, PharmD, Long Island College Hospital
- Azadeh Ghalambor, PharmD, Long Island College Hospital
- Rubiya Azmiree, PharmD, North Shore University Hospital
- Yelizaveta Matatova, PharmD, North Shore University Hospital
- Caesar Alaienia, PharmD, Stony Brook University Hospital
- Alireza Hayatshahi, PharmD, BCPS, Stony Brook University Hospital

**TOPIC:** Local Pharmacy Resident Research Presentations

**Objectives for Pharmacists:**

*At the end of the presentation the attendees should:*

- Develop strategies to implement the National Patient Safety Goal for anticoagulation
- Determine whether therapy with meropenem is appropriate first line carbapenem therapy
- Describe clinical circumstances when meropenem is a better choice than imipenem
- Demonstrate opportunity for improved utilization of proton pump inhibitors through RPh intervention
- Recognize cost savings opportunity associated with an RPh intervention in Proton Pump Inhibitor use
- Understand hydromorphone dosing
- Recognize the challenges of dosing opioids in the hospital setting
- Understand the pathophysiology of Renin-Angiotensin System related hypertension
- Provide a rationale for the use of aliskiren in the treatment of hypertension
- Understand the mechanism of action, pharmacokinetics, and pharmacodynamics of ceftobiprole
- Define the spectrum of activity of ceftobiprole against gram-positive and gram-negative organisms

**Objectives for Technicians:**

*At the end of the presentation the attendees should:*

- Understand the requirements for the National Patient Safety Goal for anticoagulation
- Understand the pharmacologic differences between meropenem and imipenem
- Understand the appropriate clinical use of proton pump inhibitors
- Understand the appropriate clinical use of hydromorphone
- Understand the appropriate clinical use of direct renin inhibitors
- Understand the appropriate clinical use of ceftobiprole

**INTENDED AUDIENCE:** Health-system pharmacists, pharmacy students, and technicians.

**Cost:** There is no charge for members of the LISHP. Non-Member charge is \$30.00.

**Sponsored by LISHP**

**RSVP by March 18, 2009: electronic responses automatically generate a reply, manual responses call Edmund Hayes at 631-444-6967**

**NEXT MEETING: April 2009**



*The NYS Council of Health-system Pharmacists (NYSCHP) is approved by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program, 134-999-09-065-L04-P; 134-999-09-065-Lo4-T, is approved for 0.2 CEU (2.0 contact hour). **Statements of Continuing Pharmacy Education Credit are mailed to participants within 30 days of receipt of the completed evaluation forms. A completed evaluation form is required to obtain continuing pharmaceutical education credit.** Payments to NYSCHP are not deductible as charitable contributions for federal income tax purposes. However, they may be deductible under other provisions of the Internal Revenue*